Mineralys Therapeutics, Inc. Board of Directors

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Ms. Sarah Foster

Ms. Sarah Foster

Vice President of Human Resources

Ms. Jessica Ibbitson

Ms. Jessica Ibbitson

Senior Vice President of Clinical Operations

Mr. Jeffrey N. Fellows

Mr. Jeffrey N. Fellows

Senior Vice President of Regulatory Affairs

Ms. Danielle Bradbury

Ms. Danielle Bradbury

Senior Vice President of Quality Assurance

Ms. Cindy Berejikian

Ms. Cindy Berejikian

Executive Vice President of Operations

Dr. Robert McKean Ph.D.

Dr. Robert McKean Ph.D.

Senior Vice President of CMC

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.